Venn Life Sciences Holdings Stock London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 72.77M | Sales 2024 * | 62.06M 80.59M | Capitalization | 183M 238M |
---|---|---|---|---|---|
Net income 2023 | 16M 20.78M | Net income 2024 * | 8M 10.39M | EV / Sales 2023 | 2.22 x |
Net cash position 2023 | 36.97M 48.01M | Net cash position 2024 * | 39.55M 51.36M | EV / Sales 2024 * | 2.31 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
22.4
x | Employees | - |
Yield 2023 |
0.84% | Yield 2024 * |
0.83% | Free-Float | 58.58% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+36.10% | 33.02B | |
-6.30% | 27.9B | |
+18.71% | 27.63B | |
+46.15% | 14.37B | |
+44.52% | 13.45B | |
+0.19% | 12.03B |